Europital announces the official launching and certification attainment of its latest product.
Europital announces the official launching and certification attainment of its latest product. From January 2015 “Penthu®: The Future of Medical Management in Clinical Trials” will be available in the market.
Penthu® is an innovative and intuitive platform that drives performance, knowledge and efficiencies in clinical trials. This electronic tool allows project team to provide timely medical guidance and effficiently manage medical issues across multiple projects with minimal effort from the user’s side, thus reducing time, energy and resources while maximizing quality, knowledge and transparency.
This communication and knowledge trasnfer platform has been developed by clinical research professional and founded in three-core principles:
Thanks to an interactive environment that provides the kind of transparency needed to share and access information, the team’s performance is increased, creating real partnerships between project members.
Recently, PenThu® became an officially registered trademark in Europe. The European OHIM issued last November 2014 the Certificate of Registration for PenThu® as a Registered Trademark in the 28 member states of the European Union.
For more information about PenThu, visit www.pethu.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.